<!DOCTYPE html><html><head><title>Myelodysplastic syndromes (MDS): percentage of higher-risk MDS patients receiving azacitidine or decitabine.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Title
</h3>
<div class='FieldValue'>
<div class="content_title">Myelodysplastic syndromes (MDS): percentage of higher-risk MDS patients receiving azacitidine or decitabine.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>American Society of Hematology (ASH). Myelodysplastic syndromes (MDS) measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 14 p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Measure Domain
</h2>
<div class='field field_picklist-one'>
<h3>
Primary Measure Domain
</h3>
<div class='FieldValue'>
Clinical Quality Measures: Process
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Secondary Measure Domain
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>

</div>
<div class='section'>
<h2>Brief Abstract
</h2>
<div class='field field_text'>
<h3>
Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure is used to assess the percentage of higher-risk (intermediate-2, or high-risk using International Prognostic Scoring System [IPSS], very high-risk using IPSS-R, and/or with excess blasts, or high- or very high-risk using World Health Organization-based Prognostic Scoring System [WPSS]) myelodysplastic syndromes (MDS) patients greater than 18 years old receiving azacitidine or decitabine.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rationale
</h3>
<div class='FieldValue'>
<div class="content_para"><p><em>Statement from the Myelodysplastic Syndromes (MDS) Task Force</em>:<br />
Recently revised National Comprehensive Cancer Network (NCCN) guidelines for MDS (2015) recommend the use of azacitidine or decitabine within the algorithm for the treatment of higher-risk MDS patients. The definition of higher risk patient was expanded to include World Health Organization-based Prognostic Scoring System (WPSS) High and Very High in 2014.</p>
<p><em>Excerpts (verbatim) from guidelines</em>:<br />
[Conventional d]rug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens&hellip; Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care (Fenaux et al., 2009).</p>
<p>[In a study to compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy&hellip;] Decitabine administered in 6-week cycles is active in older patients with higher-risk MDS, resulting in improvements of OS [overall survival] and AMLFS [acute myeloid leukemia-free survival] (nonsignificant), of PFS [progression-free survival] and AML transformation (significant), and of QOL [quality of life] (L&uuml;bbert et al., 2011).</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Rationale
</h3>
<div class='FieldValue'>
<table><tr><td>American Society of Hematology (ASH). Myelodysplastic syndromes (MDS) measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 14 p. </td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10(3):223-32. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=19230772" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011 May 20;29(15):1987-96. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=21483003" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. V1.2016. Fort Washington (PA): National Comprehensive Cancer Network (NCCN); 2015 May 28. </td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Primary Health Components
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Higher-risk myelodysplastic syndromes (MDS); International Prognostic Scoring System (IPSS, IPSS-R); World Health Organization-Based Prognostic Scoring System (WPSS); azacitidine; decitabine</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The number of myelodysplastic syndromes (MDS) patients in your selection who are higher-risk (intermediate-2, or high-risk using International Prognostic Scoring System [IPSS], very high-risk using IPSS-R, and/or with excess blasts, or high- or very high-risk using World Health Organization-based Prognostic Scoring System [WPSS]) </p>
<p>See the related "Denominator Inclusions/Exclusions" field.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The number of myelodysplastic syndromes (MDS) patients in your selection who are</p>
<ul style="list-style-type: disc;">
    <li>Higher-risk (intermediate-2, or high-risk using International Prognostic Scoring System [IPSS], very high-risk using IPSS-R, and/or with excess blasts, or high- or very high-risk using World Health Organization-based Prognostic Scoring System [WPSS])
    <p>AND </p>
    </li>
    <li>Receiving azacitidine or decitabine </li>
</ul>
<p>See the related "Numerator Inclusions/Exclusions" field.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Measure
</h2>
<div class='field field_picklist-choice'>
<h3>
Type of Evidence Supporting the Criterion of Quality for the Measure
</h3>
<div class='FieldValue'>
A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence
</div>
<div class='FieldValue'>
One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal
</div>

</div>
<div class='field field_text'>
<h3>
Additional Information Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p><em>Evidence of gap</em>:<br />
The use of azacitidine or decitabine for the treatment of higher-risk myelodysplastic syndromes (MDS) is a recent addition to the National Comprehensive Cancer Network (NCCN) guidelines. For this reason, we believe there is a gap in use of these therapeutic options. Since 2013, performance for this measure was 79% for 203 patients.</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Additional Information Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<table><tr><td>American Society of Hematology (ASH). Myelodysplastic syndromes (MDS) measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 14 p. </td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Extent of Measure Testing
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The myelodysplastic syndromes (MDS) measure set was developed by the American Society of Hematology (ASH) using a rigorous methodology (adapted from the American Medical Association [AMA]-convened Physician Consortium for Performance Improvement [PCPI]) and has been field tested. The MDS measure set was accepted by American Board of Internal Medicine (ABIM) for use with practice improvement modules meeting Part 4 of Maintenance of Certification Requirements in 2006.</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Extent of Measure Testing
</h3>
<div class='FieldValue'>
<table><tr><td>Frechette S. (Principal, Northfield Associates, LLC, Warren, VT). Personal communication. 2014 Dec 10. &nbsp;1 p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>State of Use of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
State of Use
</h3>
<div class='FieldValue'>
Current routine use
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Current Use
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Application of the Measure in its Current Use
</h2>
<div class='field field_picklist-choice'>
<h3>
Measurement Setting
</h3>
<div class='FieldValue'>
Ambulatory/Office-based Care
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Professionals Involved in Delivery of Health Services
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Least Aggregated Level of Services Delivery Addressed
</h3>
<div class='FieldValue'>
Individual Clinicians or Public Health Professionals
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Statement of Acceptable Minimum Sample Size
</h3>
<div class='FieldValue'>
Specified
</div>

</div>
<div class='field field_text'>
<h3>
Target Population Age
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Age greater than 18 years</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Target Population Gender
</h3>
<div class='FieldValue'>
Either male or female
</div>

</div>

</div>
<div class='section'>
<h2>National Strategy for Quality Improvement in Health Care
</h2>
<div class='field field_text'>
<h3>
National Quality Strategy Aim
</h3>
<div class='FieldValue'>
<ul><li>Better Care</li></ul>
</div>

</div>
<div class='field field_text'>
<h3>
National Quality Strategy Priority
</h3>
<div class='FieldValue'>
<ul><li>Prevention and Treatment of Leading Causes of Mortality</li></ul>
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Health Care Quality Report Categories
</h2>
<div class='field field_picklist-choice'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Living with Illness
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>

</div>

</div>
<div class='section'>
<h2>Data Collection for the Measure
</h2>
<div class='field field_text'>
<h3>
Case Finding Period
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Denominator Sampling Frame
</h3>
<div class='FieldValue'>
Patients associated with provider
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Denominator (Index) Event or Characteristic
</h3>
<div class='FieldValue'>
Clinical Condition
</div>
<div class='FieldValue'>
Diagnostic Evaluation
</div>
<div class='FieldValue'>
Encounter
</div>
<div class='FieldValue'>
Patient/Individual (Consumer) Characteristic
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Denominator Time Window
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions </strong><br />
The number of myelodysplastic syndromes (MDS) patients in your selection who are higher-risk (intermediate-2, or high-risk using International Prognostic Scoring System [IPSS], very high-risk using IPSS-R, and/or with excess blasts, or high- or very high-risk using World Health Organization-based Prognostic Scoring System [WPSS])</p>
<p>Patients can be included in the chart abstraction if:</p>
<ul style="list-style-type: disc;">
    <li>They have been seen by the practice within the past 18 months </li>
    <li>Management decisions regarding care are made primarily by providers in the practice </li>
    <li>They are greater than 18 years old (or the age at which your institution refers to adult hematologists) </li>
</ul>
<p class="Note"><strong>Note</strong>: Refer to the original measure documentation for a list of International Classification of Diseases, Tenth Revision (ICD-10) codes used in MDS patient selection. </p>
<p><strong>Exclusions</strong></p>
<ul style="list-style-type: disc;">
    <li>Patient with successful hematopoietic stem cell transplant </li>
    <li>Patient refused treatment </li>
</ul></div>
</div>

</div>
<div class='field field_picklist-choice-4'>
<h3>
Exclusions/Exceptions
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br />
The number of myelodysplastic syndromes (MDS) patients in your selection who are </p>
<ul style="list-style-type: disc;">
    <li>Higher-risk (intermediate-2, or high-risk using International Prognostic Scoring System [IPSS], very high-risk using IPSS-R, and/or with excess blasts, or high- or very high-risk using World Health Organization-Based Prognostic Scoring System [WPSS])
    <p>AND </p>
    </li>
    <li>Receiving azacitidine or decitabine </li>
</ul>
<p class="Note"><strong>Note</strong>: Receiving azacitidine or decitabine means you prescribed or confirmed that the patient was prescribed azacitidine or decitabine. Refer to the original measure documentation for a list of International Classification of Diseases, Tenth Revision (ICD-10) codes used in MDS patient selection and a list of Healthcare Common Procedure Coding System (HCPCS) codes for azacitidine or decitabine.</p>
<p><strong>Exclusions</strong></p>
<ul style="list-style-type: disc;">
    <li>Patient with successful hematopoietic stem cell transplant </li>
    <li>Patient refused treatment </li>
</ul></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Numerator Search Strategy
</h3>
<div class='FieldValue'>
Fixed time period or point in time
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Data Source
</h3>
<div class='FieldValue'>
Administrative clinical data
</div>
<div class='FieldValue'>
Paper medical record
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Type of Health State
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_text'>
<h3>
Instruments Used and/or Associated with the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Computation of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
Measure Specifies Disaggregation
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Scoring
</h3>
<div class='FieldValue'>
Rate/Proportion
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Interpretation of Score
</h3>
<div class='FieldValue'>
Desired value is a higher score
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Allowance for Patient or Population Factors
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Standard of Comparison
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information
</h2>
<div class='field field_text'>
<h3>
Original Title
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Measure 5: Higher-risk (intermediate-2, or high-risk using IPSS, very high-risk using IPSS-R, and/or with excess blasts, or high- or very high-risk using WPSS) MDS patient receiving azacitidine or decitabine.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Collection Name
</h3>
<div class='FieldValue'>
Myelodysplastic Syndromes Measure Set
</div>

</div>
<div class='field field_orglist'>
<h3>
Submitter
</h3>
<div class='FieldValue'>
American Society of Hematology - Medical Specialty Society
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Developer
</h3>
<div class='FieldValue'>
American Society of Hematology - Medical Specialty Society
</div>

</div>
<div class='field field_text'>
<h3>
Funding Source(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The American Society of Hematology</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of the Group that Developed the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The American Society of Hematology (ASH) Myelodysplastic Syndromes (MDS) Task Force:</p>
<ul style="list-style-type: disc;">
    <li>Lawrence A. Solberg, Jr., MD, PhD (<em>Chair</em>) </li>
    <li>Mikkael Sekeres, MD, MS </li>
    <li>Timothy Miley, MD </li>
    <li>Kenneth R. Adler, MD </li>
    <li>Steven Allen, MD </li>
    <li>David P. Steensma, Jr., MD, PhD </li>
    <li>Karen Kayoumi (ASH) </li>
    <li>Charles Clayton (ASH) </li>
    <li>Suzanne Leous (ASH) </li>
    <li>Sue Frechette, RN, MBA (Northfield Associates LLC) </li>
    <li>Debra Reis (Healthmonix) </li>
    <li>Lauren Patrick (Healthmonix) </li>
</ul></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Other Potential Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_date'>
<h3>
Date of Most Current Version in NQMC
</h3>
<div class='FieldValue'>
2017 Feb
</div>

</div>
<div class='field field_text'>
<h3>
Measure Maintenance
</h3>
<div class='FieldValue'>
<div class="content_para"><p>American Society of Hematology (ASH) reviews/updates measures annually</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date of Next Anticipated Revision
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the measure.</p>
<p>This measure updates a previous version: American Society of Hematology (ASH). Myelodysplastic syndromes (MDS) measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2015 Dec. 16 p.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Source not available electronically.</p>
<p>For more information, contact the American Society of Hematology (ASH) at 2021 L Street NW, Suite 900, Washington, DC 20036; Phone: 202-776-0544; Fax: 202-776-0545; Web site: <a href="http://www.hematology.org" title="ASH Web site">www.hematology.org</a>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NQMC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary was completed by ECRI Institute on July 20, 2015. The information was verified by the measure developer on August 27, 2015. </p>
<p>This NQMC summary was updated by ECRI Institute on April 18, 2016. The information was verified by the measure developer on May 24, 2016. </p>
<p>This NQMC summary was updated again by ECRI Institute on March 21, 2017. The information was verified by the measure developer on May 3, 2017.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.</p>
<p>For more information, contact Robert M. Plovnick, MD, MS, Director of Quality Improvement Programs at American Society of Hematology 2021 L Street NW, Suite 900 Washington, DC 20036.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Production
</h2>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>American Society of Hematology (ASH). Myelodysplastic syndromes (MDS) measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 14 p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NQMC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>
</div>

</div>

</div>
</body></html>